Healthcare economics

Estabhshes new criteria for permitting healthcare economic information relating to new drugs in labelling and advertising. 

The objective of the conference was to identify the critical issues facing the pharmacy profession in the next 15 to 20 years. Keynote speakers described trends relating to public policy, technology, healthcare economics, and healthcare delivery. C. Douglas Hepler, Ph.D. presented an address coauthored by Linda M. Strand, Pharm.D., Ph.D. on pharmacy s opportunities and responsibilities in healthcare. This presentation was a milestone for pharmacy and defined pharmaceutical care as the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient s quality of life. ... 

I 3 C-CSF and Bioequivalence The Emergence of Healthcare Economics Table 3.1 Dates of product patent introduction in EU accession countries... 

Waterson, RE. and Hutchinson, A. 2011. Use of the Hospital Survey of Patient Safety Culture - A review of the current evidence base, in S. Albolino, S. Bagnara, T. Bellandi, J. Llaneza, G. Rosal-Lopez and R. TartagUa (eds). Healthcare Economics and Patient Safety (HEPS 2011), 22-4 June 2011, Oviedo, Spain. Taylor Francis CRC Press, 473-4. 

Cardiovascular complications may occur in proportion to the decrease in renal function. Not only will patients activity of daily living (ADL) and quality of life (QOL) greatly deteriorate if they have such complications, but there will be a major problem in health and healthcare economics. 

Rovura J, Leidl R (1995) Projecting individual healthcare costs of HIV/AIDS patients in Catalonia, in FitzSimons D, Hardy V, Tolley K (eds) The economic and social impact of AIDS in Europe. Cassell, London, pp 82-89... 

A search of Medline, EMBASE and PsycLIT was conducted in August 2000, using the following terms Amisulpride, clozapine, olanzapine, risperidone, sertindole, zotepine, ziprasidone, economics, healthcare, costs. All manufacturers of atypical antipsychotic drugs were contacted in April 2000 and asked to supply primary reference data on their product, and all companies had complied with this request by August 2000. A further manual search was conducted of files and journals kept in the National Centre for Information on Psychotropics at the Maudsley Hospital. Reference sections from all retrieved papers were scrutinized for further relevant references. 

In a recent seminar, a medical expert noted that the United States has given away economic and technical dominance in industry after industry to other countries. Healthcare research is one of the few areas in which the U.S. enjoys unparalleled leadership which has enormous impact on the quality of medical care. If the healthcare industry and the academic medical enterprise falters—and this is in danger right now—I think it will be an absolute disaster for this country [40]. Many in pharmacy, medicine, and other healthcare fields would concur with the above statement. The problem is that many others in the public sector do not fully appreciate what is at stake. Pharmacists have an opportunity to help tell the story, as difficult as it sometimes is to convey. 

It is no longer sufficient to show that a drug is effective and well tolerated. With healthcare costs rising, it is necessary to provide economic measurements of the benefits that a new drug... 

A prerequisite to the use of health economics is an acceptance that no healthcare system can possibly do all things for all people. This means recognising explicitly that some form of prioritising is necessary and unavoidable. Such recognition has been slowly emerging over the past decade or so. 

The assessment of the clinical benefit of medicines is generally understood by clinicians, regulatory authorities and reimbursement authorities alike. Everyone instinctively understands the clinical benefit of decreasing a hypertensive patient s blood pressure to 130/90 or the benefit in reducing the number of strokes. However, in an era of increasing healthcare costs and funding decisions, there is a need not only to illustrate the clinical benefit of a drug, but to translate that clinical outcome into an economic benefit. 

---